Vascular Solutions to Participate in Bank of America Merrill Lynch 2013 Health Care Conference

Vascular Solutions to Participate in Bank of America Merrill Lynch 2013 Health
Care Conference

MINNEAPOLIS, May 8, 2013 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc.
(Nasdaq:VASC) today announced that the Company is scheduled to participate in
the Bank of America Merrill Lynch 2013 Health Care Conference being held at
The Encore at Wynn in Las Vegas.

James Hennen, Chief Financial Officer of Vascular Solutions, will present on
Wednesday, May 15^th at 5:00pm (PDT). To hear the live audio webcast of the
panel discussion, go to the investor relations page of the Company's web site
http://www.vasc.com and click on the "Investor Conferences" icon a few minutes
prior to start time to download any necessary software.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses
on developing unique clinical solutions for coronary and peripheral vascular
procedures. The company's product line consists of over 75 products in three
categories: catheter products, hemostat products and vein products. Vascular
Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein specialists
through its direct U.S. sales force and international independent distributor
network.

The information in this press release contains forward-looking statements,
including statements regarding the international availability of the Venture
catheter and expectations about the product's sales, that involve risks and
uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements. Important factors that may
cause such differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2012 and other recent filings with the
Securities and Exchange Commission. The risks and uncertainties include,
without limitation, risks associated with the need for adoption of our new
products, lack of sustained profitability, exposure to intellectual property
claims, significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by others, doing
business in international markets, the availability of third party
reimbursement, and actions by the FDA.

              For further information, connect to www.vasc.com.
                                      

CONTACT: James Hennen, CFO
         Phil Nalbone, VP
         Vascular Solutions, Inc.
         (763) 656-4300